Holen Sie sich die Stockscreener-App
3.22
0.63%
0.02
Handel nachbörslich:
3.26
0.04
+1.24%
Schlusskurs vom Vortag:
$3.20
Offen:
$3.2
24-Stunden-Volumen:
1.74M
Relative Volume:
0.68
Marktkapitalisierung:
$859.31M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-244.17M
KGV:
-3.2982
EPS:
-0.9763
Netto-Cashflow:
$-144.77M
1W Leistung:
+20.15%
1M Leistung:
+2.22%
6M Leistung:
-22.60%
1J Leistung:
+117.57%
1-Tages-Spanne:
$3.175
$3.36
1-Wochen-Bereich:
$2.75
$3.36
52-Wochen-Spanne:
$1.32
$6.55
Sana Biotechnology Inc Stock (SANA) Company Profile
Firmenname
Sana Biotechnology Inc
Sektor
Branche
Telefon
(206) 701-7914
Adresse
188 EAST BLAINE STREET, SUITE 350, SEATTLE
Compare SANA vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SANA
Sana Biotechnology Inc
|
3.22 | 853.97M | 0 | -244.17M | -144.77M | -0.9763 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Sana Biotechnology Inc Stock (SANA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-24 | Eingeleitet | Wedbush | Outperform |
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-03-18 | Hochstufung | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-03-14 | Eingeleitet | Jefferies | Buy |
| 2025-01-08 | Hochstufung | TD Cowen | Hold → Buy |
| 2024-11-05 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-06-26 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-01-16 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2023-09-25 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-09-05 | Eingeleitet | Citigroup | Buy |
| 2023-08-14 | Eingeleitet | TD Cowen | Market Perform |
| 2023-05-02 | Eingeleitet | H.C. Wainwright | Neutral |
| 2021-03-01 | Eingeleitet | BofA Securities | Buy |
| 2021-03-01 | Eingeleitet | Goldman | Neutral |
| 2021-03-01 | Eingeleitet | JP Morgan | Neutral |
| 2021-03-01 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Sana Biotechnology Inc Aktie (SANA) Neueste Nachrichten
Earnings Miss: Is Sana Biotechnology Inc in a long term uptrendWeekly Investment Recap & Fast Moving Stock Trade Plans - baoquankhu1.vn
InvestingPro’s Fair Value spotted Sana Biotech overvaluation early By Investing.com - Investing.com
Growth Recap: What are Sana Biotechnology Incs earnings expectationsMarket Volume Summary & Technical Buy Zone Confirmation - baoquankhu1.vn
SANA Forecast, Price Target & Analyst Ratings | SANA BIOTECHNOLOGY INC (NASDAQ:SANA) - ChartMill
SANA PE Ratio & Valuation, Is SANA Overvalued - Intellectia AI
JPMorgan Chase & Co. Raises Holdings in Sana Biotechnology, Inc. $SANA - marketbeat.com
Sana Biotechnology Inc. (SANA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Citi Maintained a Buy Rating on Sana Biotechnology (SANA) - MSN
Sana Biotech Stock Jumps A Whopping 35% After Eric Jackson Calls It ‘Next 100-Bagger Platform’ - MSN
Options Flow: Is Sana Biotechnology Inc a stock for growth or value investorsQuarterly Trade Summary & Expert Approved Momentum Ideas - baoquankhu1.vn
Aug Breakouts: How does Sana Biotechnology Inc score in quality rankingsQuarterly Profit Report & Safe Entry Trade Reports - baoquankhu1.vn
Sana Biotechnology (NASDAQ: SANA) EVP files initial ownership report - Stock Titan
Sana Biotechnology (NASDAQ:SANA) Trading Down 7.2%Here's What Happened - MarketBeat
Shorts Report: How does Sana Biotechnology Inc score in quality rankingsMarket Sentiment Review & Accurate Intraday Trade Tips - baoquankhu1.vn
Sana Biotechnology, Inc. (NASDAQ:SANA) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
SANA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
Sana Biotechnology (SANA) appoints industry veteran Brian Piper as new CFO - MSN
Bull Run: Will Sana Biotechnology Inc stock hit new highs in YEAR2026 Outlook & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
Breakouts Watch: Can Sana Biotechnology Inc be the next market leaderDay Trade & High Accuracy Buy Signal Tips - baoquankhu1.vn
H.C. Wainwright reiterates Sana Biotechnology stock buy rating - Investing.com
Sana Biotechnology reports 14-month data on diabetes cell therapy By Investing.com - Investing.com India
Integral Health Asset Management LLC Has $7.10 Million Stock Position in Sana Biotechnology, Inc. $SANA - MarketBeat
Morgan Stanley Maintains Overweight on Sana Biotechnology, Inc. (SANA) March 2026 - Meyka
Morgan Stanley reiterates Sana Biotechnology stock rating on diabetes data By Investing.com - Investing.com Canada
Sana Biotechnology (NASDAQ:SANA) Trading Up 7.8%Here's What Happened - MarketBeat
Sana Biotechnology Announces Continued Positive Clinical Results Through 14 Months from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression - Bitget
Sana Biotechnology reports 14-month data on diabetes cell therapy - Investing.com
Analysts Offer Insights on Healthcare Companies: Sana Biotechnology (SANA) and Rapport Therapeutics, Inc. (RAPP) - The Globe and Mail
Earnings Report: Will Sana Biotechnology Inc benefit from sector rotation2026 Earnings Surprises & Consistent Return Investment Signals - baoquankhu1.vn
SANA: Hypoimmune and in vivo CAR T platforms advance toward clinical trials, with key data expected soon - TradingView
Sana (SANA) CEO Steve Harr vests RSUs and uses 24,345 shares for tax - Stock Titan
Sana Biotechnology (SANA) officer exercises RSUs and withholds shares for taxes - Stock Titan
VIX Spike: Can Sana Biotechnology Inc be the next market leader2026 Chart Watch & Comprehensive Market Scan Reports - baoquankhu1.vn
Sana Biotechnology (SANA) Expected to Announce Quarterly Earnings on Monday - marketbeat.com
Sana Diabetes Data And Funding Moves Reframe Risk For NasdaqGS SANA Investors - Sahm
SANA Should I Buy - Intellectia AI
Aug Drivers: Is Sana Biotechnology Inc attractive at current valuation2025 Market Trends & Short-Term High Return Ideas - baoquankhu1.vn
Sana Biotechnology (SANA) CEO granted 200,000 RSUs and 900,000 stock options - Stock Titan
TD Cowen reiterates Buy rating on Sana Biotechnology stock By Investing.com - Investing.com Canada
TD Cowen reiterates Buy rating on Sana Biotechnology stock - Investing.com UK
Q1 EPS Estimate for Sana Biotechnology Lowered by Analyst - MarketBeat
Sana Biotechnology (SANA) awards RSUs and stock options to officer - stocktitan.net
Sana Biotechnology (NASDAQ:SANA) Stock Price Down 9.7% After Analyst Downgrade - MarketBeat
What is HC Wainwright's Forecast for SANA FY2030 Earnings? - MarketBeat
Seattle InnoCajal raises $96M I Layoffs at Sana - The Business Journals
Sana Biotechnology (NASDAQ:SANA) Cut to Hold at Zacks Research - MarketBeat
Citizens reiterates Sana Biotechnology stock rating on pipeline progress By Investing.com - Investing.com Nigeria
AI Adoption Exposes Sana Biotechnology to Rising Data, Compliance, and Reputational Risks - TipRanks
Sana Biotechnology (SANA) officer exercises RSUs, uses 491 shares for taxes - Stock Titan
Sana Biotechnology Diabetes Data And CAR T Plans Shape Pipeline Outlook - simplywall.st
Sana Biotechnology (SANA) Q4 2025 Financial Results: Net Loss and Analyst OutlookNews and Statistics - IndexBox
Finanzdaten der Sana Biotechnology Inc-Aktie (SANA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Sana Biotechnology Inc-Aktie (SANA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Harr Steve | President & CEO |
Mar 06 '26 |
Option Exercise |
0.00 |
41,666 |
0 |
7,918,596 |
| Wyrick Susan D. | See Remarks |
Mar 07 '26 |
Option Exercise |
0.00 |
3,250 |
0 |
200,583 |
| Wyrick Susan D. | See Remarks |
Mar 06 '26 |
Option Exercise |
0.00 |
10,416 |
0 |
197,333 |
| Wyrick Susan D. | See Remarks |
Mar 02 '26 |
Option Exercise |
0.00 |
1,525 |
0 |
187,408 |
| Wyrick Susan D. | See Remarks |
Jan 02 '26 |
Option Exercise |
0.00 |
7,500 |
0 |
188,290 |
| Wyrick Susan D. | See Remarks |
Dec 13 '25 |
Option Exercise |
0.00 |
3,400 |
0 |
181,663 |
| Wyrick Susan D. | See Remarks |
Dec 03 '25 |
Option Exercise |
0.00 |
10,000 |
0 |
180,828 |
| Wyrick Susan D. | See Remarks |
Jun 03 '25 |
Option Exercise |
0.00 |
10,000 |
0 |
170,395 |
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):